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he public interest in cannabis for medical use is acknowledged, and anecdotal reports of 
effectiveness in individual patients are compelling. Our objective isto make overview of 
the current scientific papers for medicinal cannabis use in paediatric population. 
Literature review was conducted utilizing, PubMed, Medline, and Google Scholar. Cannabis 
based product have promising potential for add-on treatment of certain conditions in 
paediatrics. Well-designed Randomized Clinical Trials (RCTs) with sufficient number of patients 
are imperative to demonstrate benefit of therapeutic use. In paediatrics, the greatest evidence 
for medicinal cannabis useis for seizure disorders. RCTs have demonstrated the safety and 
efficacy of oral Cannabidiol (CBD) for treatment of seizures associated with Lennox-Gastaut or 
Dravet syndrome. 
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_________________________________________________________________________ 
INTRODUCTION  
Use of medical marijuana has become a controversial topic within the medical 
community and among national legislative levels, but many countries and states have 
allowed its use. In pediatrics, many of the misconceptions regarding the use of medical 
marijuana arise from the association of the marijuana with its psychoactive effects.  
Currently, many terms associated with marijuana are being used. Cannabis, also 
known as hemp, is a general term that refers to the three species of plants Cannabis 
sativa, Cannabis indica and Cannabis ruderalis. Cannabis has long been used for hemp 
fibre, hemp seed and their hemp oils, hemp leaves for use as vegetables and as juices, 
medical purposes and as recreational drug.  
T 
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Cannabis contains more than 460 compounds of which at least 80 of these 
are cannabinoids: tetrahydrocannabinol (delta-9-tetrahydrocannabinol, THC), the 
most psychoactive cannabinoid; delta-8-tetrahydrocannabinol;cannabidiol (CBD); 
cannabinol (CBN); cannabyciclol (CBL); cannabichromene (CBC) and cannabigerol 
(CBG) with less psychotropic effects than THC. The most studied are THC and CBD. 
Primary cannabinoid receptors are: CB1, responsible for psychoactive effects of 
cannabinoids found in the brain, and CB2 found peripherally throughout the body are 
thought to modulate pain and inflammation. 
Medical and recreational use of cannabis dates from the ancient civilization almost 
5000 years ago in Chinese medicine and after that is described also in Egyptian, Greek, 
Indian and Middle Eastern cultures. 
Medical cannabis (or medical marijuana) refers to the use of cannabis and its 
compounds, to treat disease or improve symptoms.Preliminary evidence suggests that 
Cannabis has potential beneficial effects in chronic pain and muscle spasms, in 
reduction of nausea during chemotherapy, improving appetite in HIV/AIDS, 
improving sleeping and improving tics in Tourette syndrome and treating severe 
forms of epilepsy including treatment resistant epilepsy, Lennox-Gastaut syndrome 
(LGS) and Dravet syndrome (DS).  
Synthetic cannabinoids are available for prescription use in many countries. Food and 
Drug administration (FDA) has approved two oral cannabinoids for use as 
medicine: dronabinoland nabilone,the only current cannabinoids available by 
physician prescription.Dronabinol is a synthetic THC listed as Schedule II, while, 
Nabilone, is a synthetic cannabinoid listed also Schedule II, indicating high potential 
for side effects and addiction. 
The objective of this paper is to make overview of the current scientific papers for 
medicinal cannabis use in pediatric population. 
METHODS 
Conducted was a systematic and literature review of the literature on the use of 
medical cannabis in children and adolescents. PubMed, Medline, and Google Scholar 
were searched for scientific papers publishedduring the last five years, including 
systematic reviews, clinical trials, clinical studies, meta-analysis, multicenter studies, 
observational studies, randomized controlled trials and case reports by using the 
following medical terms and keywords: “cannabinoids”, “cannabis”, “cannabidiol” 
(CBD), “medical marijuana”, “dronabinol”, “nabiolone”, “tetrahydrocannabinol” (THC). 
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Filters were managed by inclusion of publications in the last 5 years, published in 
English language, studies conducted in humans and age from birth to 18 years.  
RESULTS 
PubMed, Medline, and Google Scholar searches yielded 2843 published articles and 
citations published from year 2015 to 2019. Included were case reports, clinical 
studies, clinical trials, meta-analysis, multicenter studies, observational studies, 
randomized controlled studies and systematic reviews and reviews and the search 
result were decreased to 598 published papers.After adjusting the search results, 
excluded were articles with the sample being older than 18 years, those about drug 
abuse or intoxication and effects of cannabis consumption, exposure and addiction, 
cannabis withdrawal and cannabis use disorders. The remainingcitations were 
identified for final inclusion, describing 13 reviews; 9 clinical trials of which 
3randomized controlled trials, 1 prospective study, 1 retrospective study; 3 clinical 
studies and 5 case reports.Of the all medical conditions studied in these papers, the 
most common indication was for seizures; motor disorders; chemotherapy induced 
nausea and vomiting (CINV); neurodevelopmental and behavioral conditions and 
posttraumatic stress.  
Articles about the use of cannabis in seizures includedstudies of treatment-resistant 
epilepsy (TRE), LGS and DS.Epilepsy is one of the most common chronic disorders of 
the brain affecting around 70 million people worldwide, 30% of which are resistant to 
antiepileptic therapy. LGS and DS are severe, refractory epilepsy syndromes with 
onset in early childhood and in most of the cases currently available treatments fail to 
control seizures, therefore remains the need to identify new treatments.An open 
label,large prospective study that was conducted to characterize the changes in 
response to a pharmaceutical formulation of highly purified CBD, included 72 children 
with TREwho used CBD during 48 weeks, reports significant improvements in adverse 
events, seizure severity and seizure frequency. Another study of a phase 1 trial of CBD 
in children with treatment-resistant epileptic encephalopathy where 28 children were 
included reports that CBD Cannabis extracts is safe and well tolerated for pediatric 
patients with refractory epilepsy and improves the frequency and duration of 
seizures. Double-blind placebo controlled trial conducted at 30 clinical centers that 
included 225 patients with LGSwho used CBD reported a great reduction in the 
frequency of drop seizures. Another double blind placebo controlled trial conducted at 
24 clinical sites with included 171 patients with LGS reported that add-on CBD is 
efficacious for the treatment of patients with drop seizures associated with LGS and is 
generally well tolerated. Double-blind placebo controlled trial, which included 120 
children with Dravet syndrome who received CBD, or placebo concluded that CBD 
resulted in greater reduction in seizure frequency than placebo (Devinsky et al. 2017). 
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Another study suggests that CBD might reduce seizure frequency and might have an 
adequate safety profile in children and adolescents with treatment-resistant epilepsy 
(Devinsky et al. 2016). An observational longitudinal study conducted in 57 patients 
with epilepsy of different etiology treated with CBD-THC suggests that adding CBD 
enriched cannabis extract to the treatment regimen may result in significant reduction 
in seizure frequency according to parental reports. An observational study conducted 
by a survey that included 15 patients with refractory epilepsy, suggests a possible 
beneficial effect of CBD on the control of seizures and on the improvement of 
neurocognitive aspects in patients with refractory epilepsy. 
Lattanzi et al. provide a critical review of the pharmacology of CBD and the most 
recent clinical studies that evaluated its efficacy and safety as an adjunctive treatment 
of seizures associated with LGS and DS. A review reported that CBD shows similar 
efficacy in the severe pediatric epilepsies to other antiepileptic drugs. Three 
randomized, placebo-controlled, double blind trials in DS and LGS found that CBD 
produced a 38% to 41% median reduction in allseizures compared to 13% to 19% on 
placebo. Similarly, CBD resulted in a 39% to 46% responder rate (50% convulsive or 
drop-seizure reduction) compared to 14% to 27% on placebo.Elliot et al. performed a 
systematic review of studies involving the use of cannabis to treat pediatric epilepsy, 
providing an up-to-date summary of the available evidence about the use 
of cannabis in children with TRE. In an open-label trial, patients with severe, 
childhood-onset, TRE, who were receiving stable doses of antiepileptic drugs before 
study entry, were enrolled in an expanded-access programme at 11 epilepsy centers 
across the USA. Findings suggest that CBD might reduce seizure frequency and might 
have an adequate safety profile in children and young adults with highly TRE. One 
study estimated the efficacy and safety of CBD as adjunctive treatment in patients with 
epilepsy using meta-analytical techniques that included four trials involving 550 
patients with LGS and DS were included.  
Tuberous sclerosis complex (TSC), an autosomal-dominant genetic disorder, usually 
manifests with epilepsy, affecting approximately 85% of patients, 63% of whom 
develop TRE. Findings of a study that evaluated the efficacy, safety, and tolerability 
of CBD as an adjunct to current antiepileptic drugs in patients with refractory epilepsy 
in the setting of TSC suggest that CBD may be an effective and well-tolerated 
treatment. 
Libzon et al.studied the efficacy, safety, and tolerability of medical cannabis in children 
with complex motor disorder, while two products of CBD enriched 5% oil formulation 
of cannabis were compared: one with 0.25% THC 20:1 group, the other with 0.83% 
THC 6:1 group in 25 children and adolescents. Significant improvement in spasticity 
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and dystonia, sleep difficulties, pain severity, and QOL was observed in the total study 
cohort, regardless of treatment assignment. Published paper of a case report of a 
patient suffering from treatment-resistant Tourette syndrome showed that 
administration of a THC-CBD showed a rapid and highly significant improvement in 
the Yale Global Tic Severity Scale. Jakubovskiand Muller reported two cases of 
treatment-resistant Tourette syndrome (TS) with incapacitating stuttering-like 
speech disfluencies caused by vocal blocking tics and palilalia who received 
dronabinol, suggesting that cannabis-based medicine appears to be effective in 
treatment-resistant TS patients with vocal blocking tics. 
Children with ASD commonly have comorbid symptoms such as aggression, 
hyperactivity and anxiety. It is estimated that 25% of children with treatment-
resistant epilepsy have comorbid autism spectrum disorder (ASD).Based on parents’ 
reports, findings suggest that CBD may be effective in improving ASD comorbid 
symptoms. A review of the scientific literature suggests that CBD has promising 
results in the treatment of ASD. Currently, one ongoing clinical study is assessing the 
tolerability and efficacy of a CBD and THC combination product in treating behavioral 
problems in children with ASD.Reported are cases of marijuana treatment in patients 
with developmental and behavioral conditions including high-functioning autism 
spectrum disorder, attention-deficit/hyperactivity disorder (ADHD)-combined type, 
anxiety, and depression, mild intellectual disability, and schizoaffective disorder. 
Hadland et al. review describes the role of the endocannabinoid system in normal 
neurodevelopment and discusses some of the proposed uses of cannabis in ADHD and 
ASD. Nausea and vomiting remain a problem for children undergoing treatment for 
malignancies despite new antiemetic therapies.  
A review included 34 studiesofrandomized controlled trials (RCTs) that compared a 
pharmacological antiemetic, cannabinoid, or benzodiazepine with placebo or any 
alternative active intervention in children with cancer who were to receive 
chemotherapy and reported cannabinoids to be effective. One review examines the 
evidence for medical marijuana as a supportive care agent in pediatric oncology. A 
multicenter retrospective review described the safety and efficacy of nabilone given to 
pediatric patients to prevent acute CINV. Oral solution of both CBD and THC was 
investigated for safety and efficacyas adjunctive therapy to opiates in pediatric 
patients with Cancer-related pain in double-blind, placebo-controlled study. The 
European Commission for sublingual spray with THC and CBD for the treatment of 
glioma granted orphan designation.Most recently, researchers have reported 
promising in vitro and in vivo studies for use of cannabinoids in Neuroblastoma.Use of 
CBD either as single agent or in combination with existing compounds and 
chemotherapy agents is a possibility to improve the antitumourigenic effects of other 
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treatments in Neuroblastoma. Epidermolysisbullosa is a rare blistering skin disorder 
that is challenging to manage because skin fragility and repeated wound healing 
causes itching, pain, limited mobility, and recurrent infections.  
Reported are 3 cases of self-initiated topical CBD use in patients with Epidermolysis 
bullosa in an observational study. All 3 reported faster wound healing, less blistering, 
and amelioration of pain with CBD use.  
One case study provides clinical data that support the use of CBD as a safe treatment 
for reducing anxiety and improving sleep in a young girl with posttraumatic stress 
disorder.Recent evidence suggests a potential anti-inflammatory effect of cannabis. 
A review presents an overview of recent literature on the use of cannabis in IBD 
focusing on pediatric IBD patients. 
Cannabinoids were investigated for possible effects in Perinatal Brain Injury and CBD 
is thought to have a protective effect on nerve cells due to its expected anti-
inflammatory properties and prevent the permanent brain damage in newborns.  
 
CONCLUSION 
Cannabis based productsbenefithas been demonstrated through many Randomized 
Clinical Trials of many conditions in pediatrics. 
 
The objective of thissystematic review was to synthesizethe current state of the 
research onmedical cannabinoids in childrenand adolescents. The use of CBD has 
gainedincreasing attention regarding its lack of psychoactive propertiesand potential 
benefits that have been noted in certain diseases such as epilepsy, ASD, motor 
disorders, anorexia associated with cancer, chronic pain and spasticity; CINV, sleep 
disorders, Tourette syndrome, multiple sclerosis. 
Cannabis-based therapies have been used to treat epilepsy for millenniabut interest in 
the use of cannabis as a treatment for pediatric epilepsy especially TRE has grown 
over the last decade exploring the potential efficacy of CBD use in children with DS 
and LGS.  
Although supporters of medical cannabis say that it is safe, further research is 
required to assess the long-term safety of its use especially given increasing 
accessibility fromstate legalization and potential psychiatric and neurocognitive 
adverse effects identifiedfrom studies of recreational cannabis use. 
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